Xiaobei Hu

613 total citations
26 papers, 477 citations indexed

About

Xiaobei Hu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Xiaobei Hu has authored 26 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Hematology. Recurrent topics in Xiaobei Hu's work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (8 papers) and Histone Deacetylase Inhibitors Research (6 papers). Xiaobei Hu is often cited by papers focused on Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (8 papers) and Histone Deacetylase Inhibitors Research (6 papers). Xiaobei Hu collaborates with scholars based in China, Germany and United States. Xiaobei Hu's co-authors include Yubo Zhou, Jia Li, Jia Li, Lei Xu, Yanan Duan, Jingya Li, Yiqiu Zhang, Yushen Gu, Lingyan Wu and Haowen Jiang and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and Cancer Letters.

In The Last Decade

Xiaobei Hu

26 papers receiving 472 citations

Peers

Xiaobei Hu
Eui‐Kyu Noh South Korea
David J. Sweeny United States
Jessica Roos Germany
Graziella Malaponte Italy
Michael W. Lago United States
Seok-Il Hong South Korea
Michael D. Serby United States
Sébastien Ronseaux United States
K. U. Weithmann Germany
Deborah Alpert United States
Eui‐Kyu Noh South Korea
Xiaobei Hu
Citations per year, relative to Xiaobei Hu Xiaobei Hu (= 1×) peers Eui‐Kyu Noh

Countries citing papers authored by Xiaobei Hu

Since Specialization
Citations

This map shows the geographic impact of Xiaobei Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobei Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobei Hu more than expected).

Fields of papers citing papers by Xiaobei Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobei Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobei Hu. The network helps show where Xiaobei Hu may publish in the future.

Co-authorship network of co-authors of Xiaobei Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobei Hu. A scholar is included among the top collaborators of Xiaobei Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobei Hu. Xiaobei Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Zhi, Yan Liu, J. Li, et al.. (2024). Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies. Journal of Medicinal Chemistry. 67(15). 12735–12759. 5 indexed citations
2.
Li, Jianan, Shihao Xu, Xiaobei Hu, et al.. (2024). Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies. Journal of Medicinal Chemistry. 67(17). 15220–15245. 12 indexed citations
3.
Chen, Beijing, Mingyang Sun, Chun Zhang, et al.. (2024). Discovery of CLPP-1071 as an Exceptionally Potent and Orally Efficacious Human ClpP Activator with Strong In Vivo Antitumor Activity. Journal of Medicinal Chemistry. 67(23). 21009–21029. 5 indexed citations
4.
Wang, Hanlin, Xiaobei Hu, Tao Wang, et al.. (2023). Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia. Nature Communications. 14(1). 1882–1882. 2 indexed citations
5.
Yan, Ziqin, Chen Liu, Dehua Xu, et al.. (2023). Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy. Journal of Medicinal Chemistry. 66(24). 16991–17025. 11 indexed citations
6.
Li, Xuemei, Chang Wang, Xiaobei Hu, et al.. (2022). Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia. Leukemia. 37(3). 539–549. 15 indexed citations
7.
Liu, Jieyu, et al.. (2022). Design, synthesis, and biological evaluation of Wee1 kinase degraders. European Journal of Medicinal Chemistry. 243. 114786–114786. 6 indexed citations
8.
Wang, Zhijia, Ning Song, Lei Xu, et al.. (2021). Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders. European Journal of Medicinal Chemistry. 218. 113341–113341. 61 indexed citations
9.
Zhou, Yubo, Yangming Zhang, Honghui Huang, et al.. (2021). Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Acta Pharmacologica Sinica. 43(4). 1091–1099. 9 indexed citations
10.
Zhang, Qian, Yuxin Wang, Chengwan Xia, et al.. (2021). Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals distinct cancer-associated fibroblasts in head and neck squamous cell carcinoma. Annals of Translational Medicine. 9(12). 1017–1017. 20 indexed citations
11.
Jin, Tingting, Lei Xu, Peipei Wang, et al.. (2021). Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile. Journal of Medicinal Chemistry. 64(20). 15069–15090. 12 indexed citations
12.
Hu, Xiaobei, Hanlin Wang, Weijuan Kan, et al.. (2020). Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. Acta Pharmacologica Sinica. 42(5). 814–823. 10 indexed citations
13.
Che, Jinxin, Mengmeng Zhang, Jian Gao, et al.. (2020). Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells. European Journal of Medicinal Chemistry. 203. 112491–112491. 6 indexed citations
14.
Zhan, Wenhu, Jinxin Che, Lei Xu, et al.. (2019). Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors. European Journal of Medicinal Chemistry. 180. 72–85. 20 indexed citations
15.
Wang, Yujie, Xiaobei Hu, Weijuan Kan, et al.. (2019). Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities. European Journal of Medicinal Chemistry. 176. 419–430. 23 indexed citations
16.
Wu, Lingyan, Mingfeng Xia, Yanan Duan, et al.. (2019). Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death and Disease. 10(6). 468–468. 112 indexed citations
17.
Xu, Lei, Tingting Jin, Xiaobei Hu, et al.. (2019). Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. European Journal of Medicinal Chemistry. 173. 44–62. 19 indexed citations
18.
Dong, Xiaowu, Jiankang Zhang, Lei Xu, et al.. (2018). Covalent docking modelling-based discovery of tripeptidyl epoxyketone proteasome inhibitors composed of aliphatic-heterocycles. European Journal of Medicinal Chemistry. 164. 602–614. 4 indexed citations
19.
Zhuang, Rangxiao, Lixin Gao, Xiaoqing Lv, et al.. (2016). Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors. European Journal of Medicinal Chemistry. 126. 1056–1070. 11 indexed citations
20.
Huang, Hejing, Huanan Liu, Chang‐Mei Liu, et al.. (2015). Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth. Cancer Letters. 360(2). 257–268. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eui‐Kyu Noh Breakdown of academic impact, for papers by David J. Sweeny Breakdown of academic impact, for papers by Jessica Roos Breakdown of academic impact, for papers by Graziella Malaponte Breakdown of academic impact, for papers by Michael W. Lago Breakdown of academic impact, for papers by Seok-Il Hong Breakdown of academic impact, for papers by Michael D. Serby Breakdown of academic impact, for papers by Sébastien Ronseaux Breakdown of academic impact, for papers by K. U. Weithmann Breakdown of academic impact, for papers by Deborah Alpert
Rankless by CCL
2026